Jade Biosciences, Inc. (JBIO): Cash & Equivalents
$88.44M
As of 2025-12-31
$107.25M
As of 2026-06-30
+58.1%
3-year compound annual growth
+80.8%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $88.44M | +27.5% | 2026-03-06, Balance as of period end |
| 2024-12-31 | $69.39M | +195.4% | 2026-03-06, Balance as of period end |
| 2023-12-31 | $23.49M | +4.9% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $22.40M | -58.7% | 2024-03-25, Balance as of period end |
| 2021-12-31 | $54.20M | n/m | 2023-03-29, Balance as of period end |
| 2020-12-31 | $4.57M | n/a | 2022-03-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Jade Biosciences, Inc. (JBIO) | 2025-12-31 | $88.44M | +27.5% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $41.16M | -37.7% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $101.58M | -68.8% |
| Capricor Therapeutics, Inc. (CAPR) | 2025-12-31 | $287.85M | n/m |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $60.18M | -43.0% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $287.42M | -48.7% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $238.20M | +93.5% |
| Fulcrum Therapeutics, Inc. (FULC) | 2025-12-31 | $197.53M | +239.3% |
| ArriVent BioPharma, Inc. (AVBP) | 2025-12-31 | $45.54M | -38.7% |
Compare JBIO, ZYME, UPB, CAPR side by side · Screen every company in Pharmaceutical Preparations ↗